Читать книгу Koniec z cukrzycą i otyłością - Mark dr Hyman - Страница 52

Wstęp

1. Garber A.J., et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008 Oct; 14(7): 933–946.

2. DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care. 2003 Mar; 26(3): 688–696.

Rozdział 1. Ukryta epidemia: Stany Zjednoczone Cukrzycy

1. Lin S.X., Pi-Sunyer E.X. Prevalence of the metabolic syndrome among US middle-aged and older adults with and without diabetes – a preliminary analysis ofthe NHANES 1999–2002 data. Ethn Dis. 2007 Winter; 17(1): 35–39.

2. http://www.who.int/mediacentre/news/releases/2007/pr61/en/index.html

3. Chan J.C., et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009 May 27; 301(20): 2129–2140. Review.

4. http://apps.nccd.cdc.gov/DDTSTRS/FactSheet.aspx (National Diabetes Fact Sheet 2007).

5. http://www.cdc.gov/diabetes/statistics/cvd/fig5.htm.

6. Lakka H.M., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002 Dec 4; 288(21): 2709–2716.

7. Ort A., et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999 Dec 10; 53(9): 1937–1942.

8. Key T., Reeves G.K., Spencer E.A. Symposium 1: Overnutrition: consequences and solutions for obesity and cancer risk. Proc Nutr Soc. 2009 Dec 3: 1–5.

9. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010 Sep 30; 363(14): 1341–1350. Review.

10. Pan A., et al. Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med. 2010 Nov 22; 170(21): 1884–1891.

11. Emerging Risk Factors Collaboration et al. Diabetes mellitus, fasting glucose, and risk of causespecific death. N Engl J Med. 2011 Mar 3; 364(9): 829–841.

12. Huang E.S., Basu A., O’Grady M., Capretta J.C. Projecting the future: diabetes population size and related costs for the U.S. Diabetes Care. 2009 Dec; 32(12): 2225–2229.

13. Seligman H.K., Schillinger D. Hunger and socioeconomic disparities in chronic disease. N Engl J Med. 2010 Jul; 363(1): 6–9.

14. Yach D., Hawkes C., Gould C.L., Hofman K.J. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA. 2004 Jun 2; 291(21): 2616–2622.

15. Ibid.

Rozdział 2. Rzeczywiste przyczyny cukrzyco-otyłości

1. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein H.C., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12; 358(24): 2545–2559.

2. Chen L., et al. Reduction in consumption of sugar-sweetened beverages is associated with weight loss: the PREMIER trial. Am J Clin Nutr. 2009 May; 89(5): 1299–1306.

3. Bhashyam S., et al. Aging is associared with myocardial insulin resistance and mitochondrial dysfunction. Am J Physiol Heart Circ Physiol. 2007 Nov; 293(5): H3063–3071.

4. Ryan A.S. Insulin resistance with aging: effects of diet and exercise. Sports Med. 2000 Nov; 30(5): 327–346. Review.

5. Gaziano J.M., et al. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 1997 Oct 21; 96(8): 2520–2525.

Rozdział 3. Siedem mitów o otyłości i cukrzycy, które każą nam chorować

1. McCarthy M.I. Genomics, type 2 diabetes, and obesity. N Engl J Med. 2010 Dec 9; 363(24): 2339–2350. Review.

2. Rappaport S.M. Implications of the exposome for exposure science. J Expo Sci Environ Epidemiol. 2011 Jan; 21(1): 5–9.

3. Lichtenstein P., et al. Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000 Jul 13; 343(2): 78–85.

4. Olshansky S.J., et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005 Mar 17; 352(11): 1138–1145.

5. Bibbins-Domingo K., et al. Adolescent overweight and future adult coronary heart disease. N Engl J Med. 2007 Dec 6; 357(23): 2371–2379.

6. Diabetes Prevention Program Research Group, Knowler W.C., et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009 Nov 14; 374(9702): 1677–1686.

7. Lim E.L., et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011 Oct; 54(10): 2506–2514.

8. Henry B., Kalynovskyi S. Reversing diabetes and obesity naturally: a NEWSTART lifestyle program. Diabetes Educ. 2004 Jan–Feb; 30(1): 48–50, 55–56, 58–59.

9. Jessani S., et al. Should oral glucose tolerance testing be mandatory following acute myocardial infarction? Int J Clin Pract. 2007 Apr; 61(4): 680–683.

10. Khaw K.T., et al. Association of hemoglobin A1c with cardiovascular disease acute mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004 Sep 21; 141(6): 413–420.

11. Yaffe K., et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 2004 Nov 10; 292(18): 2237–2242.

12. de la Monte S.M., Wands J.R. Alzheimer’s disease is type 3 diabetes – evidence reviewed. J Diabetes Sci Technol. 2008 Nov; 2(6): 1101–1113.

13. Stein J.L., Jack C.R. Jr, Weiner M.W., Toga A.W., Thompson P.M.; Cardiovascular Health Study; ADNI. Obesity is linked with lower brain volume in 700 AD and MCI patients. Neurobiol Aging. 2010 Aug; 31 (8): 1326–1339.

14. http://www.acpm.org/LifestyleMedicine.htm.

15. Haffner S.M., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339: 229–234.

16. The NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010. Apr 22; 362(16): 1463–1476.

17. The NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010. Apr 22; 362(16): 1477–1490.

18. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010. Apr 29; 362 (17): 1563–1574.

19. Taylor F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011 Jan 19: CD004816.

20. Abramson J., Wright J.M. Are lipid-lowering guidelines evidence-based? Lancet. 2007 Jan 20; 369(9557): 168–189.

21. Sirvent P., Mercier J., Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol. 2008 Jun; 8(3): 333–338.

22. Kuncl R.W. Agents and mechanisms of toxic myopathy. Curr Opin Neurol. 2009 Oct; 22(5): 506–515. PubMed PMID: 19680127.

23. Tsivgoulis G., et al. Presymptomatic Neuromuscular Disorders Disclosed Following Statin Treatment. Arch Intern Med. 2006; 166: 1519–1524.

24. Preiss D., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011 Jun 22; 305(24): 2556–2564.

25. The BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009 Jun 11; 360: 2503.

26. Newman M.F., et al. Neurological Outcome Research Group and the Cardiothoracic Anesthesiology Research Endeavors Investigators. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med. 2001 Feb 8; 344(6): 395–402.

27. Saliba J., Wattacheril J., Abumrad N.N. Endocrine and metabolic response to gastric bypass. Curr Opin Clin Nutr Metab Care. 2009 Sep; 12(5): 515–521. Review.

28. Sturm W., et al. Effect of bariatric surgery on both functional and structural measures of premature atherosclerosis. Eur Heart J. 2009 Aug; 30(16): 2038–2043.

Treść dostępna w pełnej wersji eBooka.